Zealand Pharma

Copenhagen, 2014-04-11 13:03 CEST (GLOBE NEWSWIRE) -- Copenhagen, 11 April 2014
– Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma
A/S (Zealand) shall announce transactions in the company’s shares and related
securities by executives and persons/companies closely related to them.

In this regard, Zealand announces the following transaction:

Name: Jørgen Lindegaard

Reason: Vice Chairman of the Board of Directors

Issuer: Zealand Pharma A/S

Type Shares

ISIN code: DK0060257814

Transaction: Purchase

Trading date: 10 April 2014

Market: NASDAQ OMX København A/S

Amount: 2,000

Price: DKK 65.50

Market value: DKK 131,000.00

Following the above transaction, Jørgen Lindegaard owns a total of 16,285
shares in Zealand.

***

For further information, please contact:

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications - Tel: +45 50 60 36 89, email: [email protected]

About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology
company based in Copenhagen, Denmark. Zealand specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company’s focus lies in the field of cardio-metabolic diseases,
diabetes and obesity in particular, and its lead drug invention is
lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi
for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as
Lyxumia®) is approved in several countries globally, including Europe and
Japan. In the U.S., an NDA is planned to be submitted in 2015, after completion
of the ELIXA Cardiovascular outcome study. In February 2014, Sanofi started the
pivotal Phase 3 clinical program for the Lantus®/Lyxumia® combination product
(LixiLan).

Zealand has a partnering strategy for the development and commercialization of
its products and, in addition to the license agreement with Sanofi in Type 2
diabetes, the company has partnerships with Boehringer Ingelheim in
diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in
chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: zealandpharma.com

AI Terminal